Cellular Biomedicine Group Inc (CBMG)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Bizuo Liu
Employees:
193
19925 STEVENS CREEK BLVD., SUITE 100, CUPERTINO, CA 95014
(408) 973-7884

• *** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

Cellular Biomedicine Group, Inc. is a biopharmaceutical company. The company engages in the development of treatments for degenerative and cancerous diseases utilizing proprietary cell-based technologies. Its technology include immune cell therapy for treatment of a range of cancers using Chimeric Antigen Receptor T cell, cancer vaccine, and T Central Memory cell technology; and human adipose-derived mesenchymal progenitor cells for treatment of joint and autoimmune diseases, with primary research and manufacturing facilities in China. Cellular Biomedicine Group was founded in 2009 and is headquartered in Cupertino, CA.

Data derived from most recent annual or quarterly report
Market Cap 384.691 Million Shares Outstanding19.478 Million Avg 30-day Volume 197.563 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-2.18
Price to Revenue1105.0845 Debt to Equity1.0119 EBITDA-48.982 Million
Price to Book Value7.5437 Operating Margin-17118.436 Enterprise Value378.728 Million
Current Ratio0.47 EPS Growth-0.188 Quick Ratio0.445
1 Yr BETA 0.8921 52-week High/Low 0.0 / Profit Margin-16969.8879
Operating Cash Flow Growth-30.3204 Free Cash Flow to Firm (FCFF) TTM -42.951 Million Free Cash Flow to Equity (FCFE) TTM14.382 Million
Altman Z-Score-3.1792
View SEC Filings from CBMG instead.

View recent insider trading info

Cellular Biomedicine Group Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding CBMG (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding CBMG

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2021-02-19 by AU CHUN KWOK ALAN
  • 4: filed on 2021-02-19 by JI GANG JACKY
  • 4: filed on 2021-02-19 by BELMONT TERRY
  • 4: filed on 2021-02-19 by ZHOU HANSHENG
  • 4: filed on 2021-02-19 by SCHAFER EDWARD T
  • 4: filed on 2021-02-19 by LIU WEN TAO
  • 4: filed on 2021-02-19 by YAO YIHONG
  • 4: filed on 2021-02-19 by CHAN ANDREW K
  • 4: filed on 2021-02-19 by LIU TONY
  • 4: filed on 2020-04-28 by AU CHUN KWOK ALAN

    • Events (8k)

  • 8-K: filed on 2021-02-19:
    Item 2.01: Completion of Acquisition or Disposition of Assets
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 5.01: Changes in Control of Registrant
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-02-08:
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-02-01:
    Item 8.01: Other Events
  • 8-K: filed on 2021-01-29:
    Item 8.01: Other Events
  • 8-K: filed on 2020-12-04:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-10-26:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
    Item 3.02: Unregistered Sales of Equity Securities
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-08-28:
    Item 9.01: Financial Statements and Exhibits
    Item 7.01: Regulation FD Disclosure
  • 8-K: filed on 2020-08-12:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-07-13:
    Item 9.01: Financial Statements and Exhibits
    Item 7.01: Regulation FD Disclosure
  • 8-K: filed on 2020-06-29:
    Item 9.01: Financial Statements and Exhibits
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 7.01: Regulation FD Disclosure

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    SCHAFER EDWARD T

    • Director
    		 0 2021-02-19 0

    LIU WEN TAO

    • Director
    		 0 2021-02-19 0

    CHAN ANDREW K CH LEGAL OFR, CORP DEV & SEC

    • Officer
    		 0 2021-02-19 0

    LIU TONY CEO, CFO

    • Officer
    • Director
    		 0 2021-02-19 0

    BELMONT TERRY

    • Director
    		 0 2021-02-19 0

    AU CHUN KWOK ALAN

    • Director
    		 0 2021-02-19 0

    YAO YIHONG CHIEF SCIENTIFIC OFFICER

    • Officer
    		 0 2021-02-19 0

    ZHOU HANSHENG

    • Director
    		 2,270,000 2021-02-19 0

    JI GANG JACKY

    • Director
    		 0 2021-02-19 0

    NOVARTIS PHARMA AG

    NOVARTIS AG

    • 10% Owner
    		 1,458,257 2020-08-11 0

    MAPLEBROOK LTD

    • 10% Owner
    		 1,104,933 2020-02-21 0

    SAILING CAPITAL OVERSEAS INVESTMENTS FUND, LP

    • 10% Owner
    		 1,712,920 2020-02-21 0

    PAN VIKTOR

    • 10% Owner
    		 1,000,000 2020-02-21 0

    ZHOU ZHENG

    • 10% Owner
    		 371,007 2020-02-21 0

    OPEA SRL

    • Director
    		 21,052 2020-02-21 0

    TF VENTURE CAPITAL MANAGEMENT CO., LTD.

    WINSOR CAPITAL LTD

    CHIANG CHEN HSIU-LIEN

    • 10% Owner
    		 0 2020-01-28 0

    MISSION RIGHT LTD

    • 10% Owner
    		 1,030,640 2019-11-10 0

    HILLHOUSE CAPITAL ADVISORS, LTD.

    • 10% Owner
    		 235,214 2019-11-10 0

    DAI CHENGXIANG

    • 10% Owner
    		 13,750 2019-11-10 0

    ZHANG LI HELEN

    • 10% Owner
    		 16,526 2019-11-10 0

    PATEL NADIR

    • Director
    		 38,701 2018-05-18 0

    HAU BOSUN

    • Director
    		 4,784 2018-05-18 0

    MENG XIA CHIEF OPERATING OFFICER

    • Officer
    		 52,498 2017-12-31 0

    CAO WEI (WILLIAM)

    • Director
    		 174,472 2016-03-02 0

    DANGDAL INTERNATIONAL GROUP CO. LTD

    • 10% Owner
    		 2,270,000 2016-02-04 0

    WANG RICHARD L CHIEF OPERATING OFFICER

    • Officer
    		 500 2015-05-24 0

    LEUNG PAK TO

    VENTURE GARDEN LTD

    FULL MOON RESOURCES LTD

    • 10% Owner
    • CONTROLLED BY A 10% OWNERCONTROLLED BY A 10% OWNER
    		 No longer subject to file 2014-12-23 0

    XU GUO-TONG

    • Director
    		 0 2014-11-07 0

    BOLOCAN DAVID

    • Director
    		 10,000 2014-06-26 0

    GLOBAL HEALTH INVESTMENT HOLDINGS LTD.

    • FORMER 10% OWNER
    		 0 2014-06-12 0

    WONG KEITH

    • Director
    		 193,715 2014-05-30 0

    AUERBACH JEFFREY H.

    • Director
    		 0 2013-10-07 0

    DAI JIANPING

    • Director
    		 0 2013-03-29 0

    KLEIN NORMAN PAUL II CORPORATE OPERATIONS OFFICER

    • Officer
    • Director
    • 10% Owner
    		 13,832,196 2010-11-01 0

    DEMBINSKI LEO JOSEPH

    • Director
    		 4,100,000 2009-03-12 0

    EASTBRIDGE INVESTMENT GROUP CORP CEO

    • Officer
    • Director
    • 10% Owner
    		 154,020,540 2008-11-01 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    WhaleWisdom Logo

    Elevate your investments